Pacific Edge Limited (NZX:PEB) and Kaiser Permanente, a US healthcare provider, have agreed for the commercial use of the PEB’s Cxbladder tests. Kaiser Permanente has allowed the commercial use of Cxbladder by their urologists for patients being assessed for bladder cancer.
- Kaiser Permanente is one of the biggest non-profit healthcare providers in the US and has more than 12 million members;
- It operates 39 hospitals and employs approximately 23,000 physicians.
The stock of PEB is up by 75.57% to $0.230 as at 1:41 pm.